Market research
NOVA.F Novo Nordisk A/S
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 165B
- P/E ratio
- 10.67
- Analyst target
- 116.88
- Dividend yield
- 31.%
- Beta
- 0.34
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- US6701002056
- Market cap
- 165B
- P/E ratio
- 10.67
- Analyst target
- 116.88
- Dividend yield
- 31.%
- Beta
- 0.34
About
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the NOVA.F discussion.
5 years, 5 months ago
Novo Nordisk A/S is currently in a long term uptrend where the price is trading 19.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.9.
Novo Nordisk A/S's total revenue sank by 0.9% to $32B since the same quarter in the previous year.
Its net income has increased by 6.9% to $9B since the same quarter in the previous year.
Finally, its free cash flow fell by 161.3% to $-1B since the same quarter in the previous year.
Based on the above factors, Novo Nordisk A/S gets an overall score of 3/5.